Skip to main navigation
VIR logo

Press Releases

Date Title
2/10/22 Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
2/10/22 Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2
2/8/22 Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global
1/13/22 Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria
1/13/22 GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
1/11/22 GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19
1/4/22 Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Displaying 11 - 17 of 17
  • Corporate Governance
    • Charters & Governance
    • Leadership
  • Press Releases
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • SEC Filings
  • Investor Resources
    • FAQ
    • Investor Contact
    • Email Alerts
  • Financial Information
    • Quarterly Results
  • About
    • Mission
    • Leadership
  • Science
    • Platforms
    • Literature Archive
  • Pipeline
    • Our Focus
    • Our Collaborators
  • Careers
    • Join Us
    • VIRtues
    • Job Opportunities
  • Contact
  • Investors
    • Corporate Governance
      • Charters & Governance
      • Leadership
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • SEC Filings
    • Investor Resources
      • FAQ
      • Investor Contact
      • Email Alerts
    • Financial Information
      • Quarterly Results
  • Print Page
  • Email Alerts
  • RSS Feeds
  • Investor Contact
  • About
    • Mission
    • Leadership
  • Science
    • Platforms
    • Literature Archive
  • Pipeline
    • Our Focus
    • Our Collaborators
  • Careers
    • Join Us
    • VIRtues
    • Job Opportunities
  • Contact
  • Investors
    • Corporate Governance
      • Charters & Governance
      • Leadership
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • SEC Filings
    • Investor Resources
      • FAQ
      • Investor Contact
      • Email Alerts
    • Financial Information
      • Quarterly Results

vir logo white

Vir Biotechnology, Inc.
499 Illinois Suite 500
San Francisco, CA 94158
415-906-4324

email: info@vir.bio

  • LinkedIn
  • Twitter
©  Vir Biotechnology All rights reserved.
  • Privacy Policy
  • Terms of Use